Skip to main content
. 2018 Oct 18;9(11):1063. doi: 10.1038/s41419-018-0957-3

Fig. 7. AZD8055 and rapamycin inhibited the tumorigenicity of CD133 + U87-MG neurosphere cells in vivo.

Fig. 7

The mice were treated with intraperitoneal injection with DMSO, AZD855 (10 mg/kg/day), or rapamycin (1.5 mg/kg/day) for 5 days a week. The treatment started from the 7th day after implantation and lasted for ~21 days. a Representative images of bioluminescence of mice on days 7, 14, and 28 after implantation. b Quantitative analysis of these bioluminescence images for the DMSO, AZD8055, and rapamycin treatment groups. c The overall survival of mice in the DMSO, AZD8055, and rapamycin treatment groups. Data are shown as the mean ± S.D. n = 5, **P < 0.01 compared to the control, ANOVA test. d Representative images of the HE staining in tumor sections ( × 400 magnification)